Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Approved For Marketing NCT05722912

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Conditions: Graft-versus-host Disease (GVHD)

Sex: All
Sponsor: Incyte Corporation

Summary

To provide ruxolitinib through an expanded access to treat a single patient with cGVHD

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05722912). StuddyBuddy aggregates publicly available trial information.